Agoracom Blog Home

Archive for the ‘Featured’ Category

FansUnite $FANS.ca Introduces Gaming Pioneer James Keane to Board of Directors $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Posted by AGORACOM-JC at 7:14 AM on Wednesday, August 26th, 2020

  • Introduce James Keane to the Board of Directors
  • James Keane is a pioneer in the online gaming space and was a key member of the ParadisePoker.com founding team in 2001.
  • James helped grow Paradise into one of the top 3 poker sites in the world and oversaw its acquisition by Sportingbet in 2005.

Vancouver, British Columbia–(August 26, 2020) –  FansUnite Entertainment Inc. (CSE: FANS) (OTC Pink: FUNFF), (“FansUnite” or the “Company”), a technology company providing leading online gaming solutions, is pleased to introduce James Keane to the Board of Directors.

James Keane is a pioneer in the online gaming space and was a key member of the ParadisePoker.com (“Paradise”) founding team in 2001. James helped grow Paradise into one of the top 3 poker sites in the world and oversaw its acquisition by Sportingbet in 2005. James remained with Sportingbet holding the position of Manager Director for Paradise and subsequently Managing Director, Emerging Markets. After the sale of Sportingbet to William Hill and GVC Holdings, James consulted in both the online and brick and mortar casino world on growth, M&A, and business execution strategies.

James is currently the CEO of King Show Games ULC, which is an experienced, full-service game development and marketing studio. KSG has created market-leading games for land-based, social, and online casinos in Video Slot, Stepper Slot, and Video Poker. KSG has designed over 200 games and has licensed titles being played in countries all over the world.

“We are thrilled to welcome someone of James’s calibre to our team as he brings decades of experience in the gaming industry to the FansUnite Board of Directors,” said Scott Burton, CEO of FansUnite. “In addition to being one of the founding members of Paradise Poker, James has first hand experience in managing small organizations and scaling them to large entities that have created shareholder value through subsequent exits. His wealth of knowledge and experience will be a tremendous asset to our organization as we look to expand our business and grow our global footprint in the coming years.”

“As someone that has been in the gaming industry for the past 20 years, I am an advocate in backing teams that have the opportunity for global scale and mass adoption,” said Keane. “After evaluating this organization, I believe the technology and team that has been put together at FansUnite puts the Company in a position to gain market share in a rapidly growing I-gaming market. The recent acquisition of Askott Entertainment now gives us the asset base to capitalize on multiple betting verticals and I could not be more thrilled to join this board of leading gaming executives.”

James will advise the company in various matters, including M&A, financing, US opportunities, casino and emerging markets.

About FansUnite Entertainment Inc.

FansUnite is a sports and entertainment company, focusing on technology related to regulated and lawful online gaming and other related products. The principal business is operating Askott Entertainment, focusing on B2C and B2B esports products, the FansUnite Sportsbook and the website of its wholly-owned subsidiary, McBookie Limited, offering online gaming services to the UK market. FansUnite is also a provider of technology solutions, products and services in the gaming and entertainment industry and looks to acquire technology platforms and assets with high-growth potential in new or developing markets.

For further information, please contact:

Prit Singh Investor Relations at FansUnite
[email protected]
(905) 510-7636

Scott Burton Chief Executive Officer of FansUnite
[email protected]

Darius Eghdami President of FansUnite
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD-LOOKING STATEMENTS: Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue” or similar expressions to be uncertain and forward-looking. Forward-looking statements may include, without limitation, statements relating to future outlook and anticipated events; the Company’s ability to become a leading technology platform and a leader in the global I-gaming market, and to serve the gaming market; FansUnite’s potential global footprint in the esports, sports betting and casino I-gaming industry; the potential growth of the Company and the gaming market; the increased number of betting options; the ability of the Company to scale its B2B arm and maintain its B2C platforms; the Company’s unique portfolio of assets; exposure resulting from the Advertising Services provided by AGORACOM; the impact of the Advertising Services on brand awareness of the Company among small cap investors; receipt of required regulatory approval including the approval of the CSE; and discussion of future plans, projections, objectives, estimates and forecasts and the timing related thereto. Forward-looking statements are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of FansUnite to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Additional information regarding the risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s Non-Offering Prospectus dated March 27, 2020 filed on its issuer profile on SEDAR at www.sedar.com and risks related to global pandemics, including the novel coronavirus (COVID-19) global health pandemic, and the spread of other viruses or pathogens and influence of macroeconomic developments. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The forward-looking statements in this news release are made as of the date of this release. FansUnite disclaims and does not undertake to update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

$KABN.ca North America and Loop Insights $MTRX.ca Partner to Launch #AI Driven Merchant and Consumer Rewards Programs, Secured by #Biometrics and #Blockchain $MOS.ca $MOGO.ca $CTZ.ca $PTO.ca $PAY.ca

Posted by AGORACOM-JC at 10:45 AM on Tuesday, August 25th, 2020
kabn-square-new
  • Announced an initial partnership agreement with Loop Insights Inc. (MTRX:TSXV), a provider of contactless solutions and artificial intelligence to drive automated marketing, contact tracing, and contactless solutions to the brick and mortar space
  • As the world goes more digital and more “check-ins” are required for contact tracing purposes, KABN NA can also enhance Loop’s contact tracing check-in solution with its proprietary blockchain technology.
  • The global blockchain market size is expected to grow from USD 3.0 billion in 2020 to USD 39.7 billion by 2025, at an impressive Compound Annual Growth Rate (CAGR) of 67.3% during 2020-2025 (source: www.marketsandmarkets.com).

TORONTO, ON and VANCOUVER, BC / August 25, 2020 / KABN Systems NA Holdings Corp. (CSE:KABN) (“KABN NA” or “KABN North America”), a Canadian Fintech company that specializes in continuous online identity verification, management and monetization in Canada and the US , is pleased to announce an initial partnership agreement with Loop Insights Inc. (MTRX:TSXV) (“Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive automated marketing, contact tracing, and contactless solutions to the brick and mortar space.

TOGETHER, THE COMPANIES WILL CREATE A VERIFIED DIGITAL ID CHECK-IN SYSTEM FOR LARGE SCALE VENUES

As the world goes more digital and more “check-ins” are required for contact tracing purposes, KABN NA can also enhance Loop’s contact tracing check-in solution with its proprietary blockchain technology. The global blockchain market size is expected to grow from USD 3.0 billion in 2020 to USD 39.7 billion by 2025, at an impressive Compound Annual Growth Rate (CAGR) of 67.3% during 2020-2025 (source: www.marketsandmarkets.com).

KABN NA’s Liquid Avatar program increases the security within Loop’s services. Customer information and identities are protected by blockchain technology- the highest level of protection. This identity verification enhancement for Loop comes at a great time. It accelerates conversations with large scale business development opportunities, such as schools, stadiums, and governments that are reopening and seek fast and secure contact tracing check-in platforms.

COMBINATION OF LOOP AND KABN NA TECHNOLOGIES RESULTS IN POWERFUL AND COMPLIANT SOLUTION FOR MERCHANTS

KABN NA, in its simplest form, turns the major problem of data privacy into a profit for individuals by giving them complete control over what data is visible on sites and platforms throughout the web.

In order to deliver this level of control, KABN has created Liquid Avatar, a powerful platform that allows users to create digital icons representing their online personas. An individual can create different Liquid Avatars to share different levels of private data with different facets of their life, such as social media, professional, business, e-commerce, and banking.

Every Liquid Avatar is biometric and blockchain secured.

On the other hand, Loop Insights provides merchants with a turnkey solution, driven by artificial intelligence. This allows them to unlock their bricks and mortar data in real-time to make smarter, faster, data-driven decisions that deliver personalized promotions and targeted engagement-leading to higher conversions and transaction revenue in professional sports, entertainment, and retail industries.

As a result of the partnership that converges the powerful technologies of both Loop and KABN NA, the tremendous value will be created for retailers and e-commerce stores due to transacting with known users who have been biometrically verified identity with a blockchain-enabled digital wallet.

In turn, this will provide merchants with the ability to push, customized offers, promotions, and other incentives based on permission-based data to a known, real person. This is extremely valuable in an environment fraught by bots and fake accounts.

NEW BUSINESS MODELS AND REVENUE STREAMS FULLY COMPLIANT WITH GLOBAL DATA PRIVACY LAWS

Moreover, the combination of these powerful standalone technologies will provide Loop and KABN NA with new business models that are compliant with jurisdictional privacy laws and regulations, where the user has management and control over the data.

KABN NA CEO, Ben Kessler: “We are very excited to partner with Loop to create a more interactive and rewarding experience for consumers. We believe that combining our efforts and solutions builds both a robust data and identity verification platform as well as, a personalized, customer-first loyalty solution. We look forward to leveraging all of these enhanced capabilities to expand our retail client and brand partner opportunities.”

Loop CEO Rob Anson: “The convergence of Loop’s IoT and AI technology with KABN NA’s Blockchain and digital identity platform is compelling and will lead to many new possible global revenue opportunities. This exciting partnership unlocks potential new ways for us to monetize our services, expand our client networks, and further accelerate our pursuit on a global scale.”

PARTNERSHIP UNLOCKS NEW WAYS FOR LOOP TO FURTHER MONETIZE ITS INSIGHTS AND ENGAGEMENT PLATFORM THROUGH RETAIL CLIENTS AND BRAND PARTNERS

Under the partnership, Loop will participate in potential revenue generated from KABN NA’s Liquid Avatar program, which includes a percentage of the sign-ups, commissions, and service fees that KABN generates from brands, retailers, other businesses, and affiliates. Loop intends to leverage brand and corporate interest to gain revenue from its third-party programmatic advertising platform.

Combining Loop’s AI-powered retail analytics and engagement with KABN’s Liquid Avatar digital identity platform, KABN KASH, a cashback and loyalty engine, and the KABN Visa card program, the partnership will create new revenue-generating opportunities for Loop. In addition to Loop’s current engagement service offerings, Loop will now be able to offer KABN KASH (cashback and rewards) and the KABN Card to its growing base of retailers and in so doing, expand its monetization efforts, while also growing its base of users and user-generated data.

This Press Release Is Available On The Loop Insights Verified Forum On AGORACOM For Shareholder Discussion and Q&A https://agoracom.com/ir/LoopInsights/forums/discussion and the KABN NA verified forum https://agoracom.com/ir/KABN

About KABN North America – www.kabnnaholdco.com

KABN Systems NA Holdings Corp. through its wholly owned subsidiary KABN Systems North America Inc. focuses on the verification, management and monetization of digital identity, empowering users to control and benefit from its use of their online identity.

KABN propriety technology suite includes 4 key products:

Liquid Avatar allows users to create high quality digital icons representing their online personas. These icons, in conjunction with KABN ID, allows users to manage and control their Digital Identity and to use Liquid Avatars to share public and permission based private data when they want and with whom they want. www.liquidavatar.com

KABN ID is an Always On, biometric and blockchain based digital identity validation and verification platform allowing users to continuously and confidently prove themselves throughout the online community.

KABN Card is a Visa approved prepaid card program allowing users to manage both digital and fiat currencies and earn cashback and other loyalty incentives. www.kabncard.com

KABN KASH is a cashback, loyalty and engagement program that powers the KABN revenue ecosystem.

KABN provides its products and services at no cost to consumers and generates revenues through permission-based partner programs. www.kabnkash.com

For more information, please visit www.kabnnaholdco.com or www.kabnsystemsna.com

For further information, please contact:

Ben Kessler
Chief Executive Officer
647-725-7742 Ext. 700
[email protected]

About Loop Insights: Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia.

For more information, please contact:

Loop Insights Inc.
LOOP Website
: www.loopinsights.ai
Rob Anson, CEO
Facebook: @LoopInsights
T: +1 877-754-5336 Ext. 4
Twitter: @LoopInsights
E: [email protected]
LinkedIn: @LoopInsights

The TSXV and CSE have not reviewed and do not accept responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only LOOP and KABN NA beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of LOOP and KABN NA’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but is not limited to, information concerning the ability of LOOP and KABN NA to generate revenues, roll out new programs and to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, LOOP and KABN NA are alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, LOOP and KABN NA have made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although LOOP and KABN NA believe that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and LOOP and KABN NA do not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to LOOP and KABN NA or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE: KABN Systems NA Holdings Corp.

Empower Clinics $CBDT.ca Reports Q2 2020 Results with 56% Revenue Increase and YTD 2020 with 130% Revenue Increase $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:03 AM on Tuesday, August 25th, 2020
  • 6,696 patient visits generating total revenue of $923,876, compared to 4,299 patient visits generating $591,023 for Q2 2019

VANCOUVER, BC / ACCESSWIRE / August 25, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF) (Frankfurt:8EC) (“Empower” or the “Company“) has filed today its unaudited condensed interim financial statements and related management’s discussion and analysis, both of which are available at www.SEDAR.com. All financial information in this press release is reported in United States dollars, unless otherwise indicated.

“Execution, operational excellence and a passion for patient care highlights a transformative quarter, in the midst of a pandemic.” said Steven McAuley, Chairman and CEO. “Our team continues to outperform, delivering triple digit first-half 2020 growth, with continued diversification of services, setting in motion our ongoing path of growth.”

Q2 2020 Highlights

  • 6,696 patient visits generating total revenue of $923,876, compared to 4,299 patient visits generating $591,023 for Q2 2019.
  • Net loss of $401,110 or $0.00 per share, compared to $1,456,506 or $0.01 per share for Q2 2019, driven by significantly reducing operating costs through aggressive headcount cuts and facility changes and a reduction in legal and professional fees and non-cash share-based payments.
  • Cash used in operating activities was $11,187, compared to $1,112,738 for Q2 2019.
  • Cash at June 30, 2020 of $305,935, compared to cash of $179,152 at December 31, 2019.

YTD 2020 Highlights

  • 12,413 patient visits generating total revenue of $1,713,011, compared to 5,497 patient visits generating $743,869 for six months ended June 30, 2019.
  • Net loss of $920,281 or $0.01 per share, compared to $1,855,047 or $0.02 per share for six months ended June 30, 2019, driven by significantly reducing operating costs through aggressive headcount cuts and facility changes and a reduction in legal and professional fees and non-cash share-based payments.
  • Cash provided by in operating activities was $2,647, compared to cash used in operating activities of $1,331,950 for six months end June 30, 2019.

Financial Summary

$, except where noted Three months ended June 30,  Six months ended June 30, 
  2020  2019  2020  2019 
Patient visits (#)  6,696   4,299   12,413   5,497 
Clinic Revenues  923,876   591,023   1,713,011   743,869 
Direct Clinic Expenses  243,905   82,750   512,305   122,163 
Loss from operations  (240,614)  (1,424,071)  (558,446)  (1,703,379)
Net loss  (401,110)  (1,456,506)  (920,281)  (1,855,047)
Net loss per share  (0.00)  (0.01)  (0.01)  (0.02)

Financial Performance

Clinic revenues for Q2 2020 and Q2 2019 were $923,876 and $591,023, respectively. This increase above prior year is attributable to the acquisition of Sun Valley and the addition of 5 clinics which drove an increase in patient count from 4,299 in Q2 2019 to 6,696 in Q2 2020.

Direct clinic expenses for Q2 2020 and Q2 2019 were $243,905 and $82,750, respectively. This increase above prior year is attributable to the increase in number of patient visits.

Loss from operations for Q2 2020 and Q2 2019 were $240,614 and $1,424,071, respectively. This decrease in net loss from operations below prior year is primarily attributable to an increase in clinic profitability with the acquisition of Sun Valley and a decrease in salaries and benefits, legal and professional fees and non-cash share-based payments expense.

Net loss for Q2 2020 and Q2 2019 were $401,110 and $1,456,506, respectively. This decrease below prior year is primarily attributable to non-cash accretion expense related to the convertible debentures and the positive impact of the Sun Valley acquisition.

During the six months ended June 30, 2020, the Company generated $2,647 in cash from operations after changes in non-cash working capital.

Please refer to the Company’s unaudited condensed interim consolidated financial statements for the three and six months ended June 30, 2020 and 2019, and accompanying Management Discussion and Analysis for a full review of the operations.

About Empower

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer

CONTACTS:

InvestorsDustin Klein Steven McAuley
 Director CEO
 720-352-1398 604-789-2146
 [email protected] [email protected]

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the direction and growth prospects of the Company, the expansion of the company’s clinic and distribution network, the expected effect of the Vendors in their new roles with the Company, the effect on the lives of patients, the growth into a national brand, the effect of the Transaction, the diversification of the Company’s business model, the potential appeal to shareholders, the growth of the Company’s patient list and the effect thereof, the expected benefits for the company’s patient base and customers, the release of the cash consideration, the release of Shares being held in escrow in connection with the Transaction and statements regarding the Company’s proprietary product line “Sollievo”. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including that the Company may not be able to expand, that the Transaction may not have the expected results, and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

CLIENT FEATURE: Innocan Pharma $INNO.ca Developing The #Pharmaceutical Guided Missile To Defeat #Coronavirus Lung Infections $GWPH $CRDL.ca $TEVA

Posted by AGORACOM-JC at 1:54 PM on Monday, August 24th, 2020
Innocan-Blog

InnoCan – Developing The Pharmaceutical Guided Missile To Defeat Coronavirus Lung Infections 

InnoCan Pharma Is A Pharmaceutical Company That Specializes In The Development Of New Drug Platforms Which Combine Unique Properties of Cannabinoids

WHY INNOCAN?

InnoCan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

PHARMACEUTICAL – THE GUIDED MISSILE

  • Revolutionary Technology Targeting Lungs Infected  With Coronavirus or other viral infections 
    • Done By Combining CBD with Stem Cell Particles (Exosomes)
    • Research & Licensing Agreement with Tel Aviv University
  • Developing CLX, The ICBM Ballistic Missile Of Coronavirus Lung Infections
  • Separate breakthrough delivery and control release technology that enables the injection of CBD.

CONSUMER RETAIL – DERMA COSMETICS 

  • A Premium Derma Cosmetics Brand
  • Containing Highly Concentrated Ingredients Formulated with CBD
  • Manufacturing & Supply Agreements – Europe and United States
  • Manufacturing Has Commenced For 9 Products As Of Q2 2020
  • Distribution Agreements – United Kingdom and Ireland

Company entered into a distribution agreement (with a Swiss CBD provider called Cloud 9 Switzerland LLC  to sell the Company’s SHIRTM Beauty and Relief & Go product lines in Italy and Switzerland.

OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF

  • Patent-Pending CBD Pain Relief Brand
  • Versions Include Spray, Roll-On and Cream
  • Relief & Go Spray – First Product Being Manufactured
    • FDA Technical Validation
    • FDA Approval To Commence Marketing In The United States
  •   Manufacturing Commencement
    • New Jersey (United States Market)
    • Portugal (Asia and Europe Markets)
  • Sales Commence In H2 2020

     SUPERIOR MANAGEMENT TEAM

  • The InnoCan Leadership Group Is Incomparable In The Small Cap World
  • Comprised Of Leading Israeli Pharmaceutical Executives
  • Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
  • Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
  • Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
  • Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.
  • Together they have built a formidable team at InnoCan

SEEING IS BELIEVING

FULL DISCLOSURE: Innocan Pharma is an advertising client of AGORA Internet Relations Corp.

Hollister Biosciences Inc. $HOLL.ca Reports Second Quarter 2020 Results With $8.47 Million In Revenue $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:25 AM on Monday, August 24th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

Multi-state operator and diversified cannabis branding company generates record quarterly revenue and delivers profitable second quarter

  • Revenue generated for the three-month period ended June 30th, 2020 was $8.47 million versus $0.2 million from the second quarter last year, representing significant year over year revenue growth
  • Revenue was primarily generated from the sale of concentrates, pre-rolls and contract manufacturing services

VANCOUVER, BC, Aug. 24, 2020 – Hollister Biosciences Inc. (CSE: HOLL), (OTC: HSTRF), (FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 230 dispensaries throughout California, and over 80 dispensaries throughout Arizona, announces financial results for the second quarter 2020 (ended June 30th, 2020).  All figures in US Dollars unless otherwise stated.

Second Quarter Financial Highlights

  • Revenue generated for the three-month period ended June 30th, 2020 was $8.47 million versus $0.2 million from the second quarter last year, representing significant year over year revenue growth
  • Revenue was primarily generated from the sale of concentrates, pre-rolls and contract manufacturing services
  • Net income for the three-month period ended June 30th, 2020 was $0.3 million compared to a net loss of $2.1 million in the first quarter of 2020

“Our second quarter results are encouraging and in line with our objective to increase revenue and profitability” shared Alex Somjen, President of Hollister Biosciences Inc.  “These financial results are a product of increased brand awareness, strategic M&A and strategic partnerships put in place over the previous six months.”

Operational Highlights and Strategic Objectives for 2020

  • The challenges presented by the COVID-19 pandemic have accelerated Hollister’s plans to roll out direct to consumer delivery
    • The brand will be called “Dreamy Delivery” and the first delivery hub is expected to launch in the fourth quarter of 2020 with statewide delivery anticipated by the end of 2021
  • Design and build-out of Hollister’s 100% owned subsidiary, Venom Extracts, in the Company’s Hollister, CA facility are underway
  • Product development and product launch associated with the Company’s joint venture with Tactical Relief and the Company’s 100% owned subsidiary, Alpha Mind Brands Inc., respectively, are progressing
  • The Company’s partnership with Tommy Chong’s Cannabis is progressing well, with Tommy Chong’s Full Spectrum Elixir now being distributed in 20 dispensaries throughout the state of California by Hollister’s distribution partner Indus Holdings Inc. (CSE: INDS)

“Enormously proud of our teams in Arizona & California.  Our staff continues to overcome obstacles like the global pandemic while posting record revenue numbers. We look forward to continuing to execute on our plans while increasing value for our shareholders.” Said Carl Saling CEO of Hollister Biosciences.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website:www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/hollister-biosciences-inc-reports-second-quarter-2020-results-301116831.html

SOURCE Hollister Biosciences Inc.

Avicanna $AVCN.ca Advances its Supply Chain Business with Commercial Exports of #CBG And #CBD into the United States and Germany as well as Industrial Scale #THC Quota Granted by the Colombian Authorities $KHRN.ca $TRUL.ca $VFF.ca

Posted by AGORACOM-JC at 8:17 AM on Monday, August 24th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • The export of the CBG isolates into the United States is part of the first known industrial cultivation, extraction, and purification of cannabigerol (“CBG”) in Colombia, validating the Company’s early mover advantage in proprietary genetics, extraction, and high margin input materials.
  • The commercial THC cultivation quota for 11,587 psychoactive plants will be used for commercial production of THC derivatives for exports.
  • The group of exports into the United States were also piloted as a part of a global tracking system through StrainSecure™, a brand of TruTrace Technologies.

TORONTO, Aug. 24, 2020 – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces that through its majority owned subsidiary, Santa Marta Golden Hemp S.A.S. (“SMGH“), the company has completed exports of CBG and CBD isolates into the United States, CBD isolate into Germany and the commencement of a pilot tracking system for the export of its active pharmaceutical ingredient (“API“) products in partnership with TruTrace Technologies Inc. (“TruTrace“) (CSE: TTT) (OTCQB: TTTSF). The Company is also pleased to announce that the Colombian Ministry of Justice and Law has granted SMGH a commercial and industrial cultivation quota for 12,264 THC plants by.

The export and sale of the commercial lot of isolated CBG into the United States was completed in parallel with commercial export of isolated CBD into the United States, as well as a pilot export for R&D purposes of CBD into Germany. The cultivation, extraction and purification of these cannabinoids including the rare cannabinoid, CBG, were all completed through Avicanna’s vertical integration at SMGH and validate the company’s innovation and leadership in natural rare cannabinoid production. The products are part of the Aureus™ product portfolio that now includes feminized seeds and advanced formulations as well as CBD, CBG and THC API products.

“This is another massive accomplishment for our team in Colombia as we enter the largest market in the world for non-psychoactive cannabinoids with our proprietary CBG offering. As the cannabinoid-derived products sector continues to evolve, our Aureus branded portfolio continues to advance in order to cater to the needs of our cosmetics and pharmaceutical partners, which require an innovative, credible, thoroughly-tested, organic, sustainable and economical source of input materials. Additionally, with the support of TruTrace, the Aureus products will be provided with traceability and trackability all the way back to the seed through a secured blockchain system.” – Aras Azadian, Chief Executive Officer of Avicanna.

The Colombian Ministry of Justice and Law granted SMGH a supplementary cultivation quota to cultivate 12,264 psychoactive cannabis plants. 11,587 plants will be destined to produce dry flower which will then be used to manufacture psychoactive derivatives for commercial production for export. The remaining 677 plants will be utilized for psychoactive derivatives for the purposes of research and development and pilot production of Avicanna’s RHO Phyto™ branded products in Colombia.

Lucas Nosiglia, President of Avicanna LATAM commented: “This achievement took years of characterization, evaluation and planning which will finally allow Avicanna to produce our THC products and export THC derivatives to our international partners. As one of the only companies permitted to produce THC commercially for the global market, we can focus on less competitive and high margin products.”

To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

About StrainSecure™ by TruTrace

Designed specifically by TruTrace for the cannabis industry, StrainSecure™ is a fully integrated software platform, secured on blockchain which aggregates and authenticates all testing and quality assurance data on products and verifies the quality of each batch and lot in distribution. Furthermore, this deployment will mark the first utilization by TruTrace of the OrionOne™ global freight and logistics solution in the cannabis sector thereby providing dynamic visibility of verified Aureus products through the entire international shipping process.

About Avicanna

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of SMGH to continue to complete exports of CBD and CBG isolates to the United States and Germany, SMGH’s ability to continue selling CBD and CBG isolates in the United States and Germany, SMGH’s ability to make use of the supplementary cultivation quota granted by the Colombian Ministry of Justice and Law, the ability of the Company to produce THC products using API produced by SMGH, and the ability of SMGH to export THC derivatives internationally. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

VIDEO: Loop Insights $MTRX.ca Pilot In 20 Locations Of Biggest CBD Retailer In America Could Lead To 550 Stores $QUIS.ca $MCLD.ca $NXO.ca

Posted by AGORACOM-JC at 5:08 PM on Thursday, August 20th, 2020
Loop Insights – Medium

Loop Insights (MTRX:TSXV) could very well be the best e-commerce technology company we’ve seen in the past 10 years.  We thought it when we saw it for the first time … and then the thinking really took hold when we showed Loop’s technology to retailer friends of ours, who jumped out of their phones.  

So what does Loop do? 

As their name suggests, they close the loop between brick and mortar locations and their e-commerce stores

But how do they do that?

Well, we know that all e-commerce sites have easy access to real-time insights, which leads to personal marketing.  That’s how:

  • Amazon recommends a product based on a real-time purchase you are making;
  • Spotify recommends music based on music you are listening to in real-time; 
  • NetFlix recommends other movies based on what you just watched.

What Loop is doing is creating that same experience for you in a physical retail location, which has NEVER been done.  Whether you are in a hotel, casino, store, or stadium, Loop’s disruptive capability creates a real-time increase in spend, loyalty, foot traffic and wallet share.   But don’t just take our word for it, here is what the largest brick & mortar CBD retailer in America had to say:  

“There’s no greater time to utilize top-tier artificial intelligence technology to gain an edge in this industry. Our customer base is huge, and it’s important to understand their needs and preferences to maximize basket size, loyalty and wallet share. We look forward to working with Loop and building unparalleled experiences for our customers.”

  If that wasn’t enough, here is what MTRX announced last month:  

Now you know why we’re calling Loop Insights the best e-commerce technology company we’ve seen in 10 years.  

Grab your favourite summer beverage, get comfortable and watch this powerful video with CEO, Rob Anson.    

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

Innocan $INNO.ca to Distribute Its #CBD Line of Products in Italy and Switzerland $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 4:07 PM on Thursday, August 20th, 2020
Innocan-Blog
  • Entered into a distribution agreement with a Swiss CBD provider called Cloud 9 Switzerland LLC to sell the Company’s SHIR Beauty and Relief & Go product lines in Italy and Switzerland
  • Cloud 9 will distribute Innocan’s unique cosmetic CBD products in Italy and Switzerland on a nonexclusive basis

Herzliya, Israel and Calgary, Alberta–(August 20, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce that its wholly owned subsidiary, Innocan Pharma Ltd. (“Innocan Israel“) has entered into a distribution agreement (the “Agreement“) with a Swiss CBD provider called Cloud 9 Switzerland LLC (“Cloud 9“) to sell the Company’s SHIRTM Beauty and Relief & Go product lines in Italy and Switzerland.

Under the terms of the Agreement, Cloud 9 will distribute Innocan’s unique cosmetic CBD products in Italy and Switzerland on a nonexclusive basis. The Agreement defines the ordering and delivery mechanisms for the products and the marketing cooperation between the parties. The parties intend to carry out the Agreement immediately, following the completion of all registration and regulatory requirements in Italy and Switzerland.



Figure 1

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6922/62207_556f93134488c88c_002full.jpg

“In these extraordinary times, cannabis based pharma and cosmetic products respond to consumers’ desires for a more natural and healthy lifestyle. Innocan has a proven high-level expertise and shared vision making them an ideal partner for us to develop these new markets,” said Cloud 9’s Founder and Managing Director, Dr. Francis Scanlan.

Iris Bincovich, Innocan’s Founder and CEO, commented, “We are excited to have our products distributed in Switzerland and Italy. This is the second distribution agreement we have signed in Europe. I believe Cloud 9 will provide professional distribution of our SHIR and Relief & Go product lines.”

Additionally, on July 7, 2020, the Company has engaged AGORACOM for investor awareness, marketing and branding services (the “Services“) for a 12-month online marketing campaign to engage current shareholders and the broader investment community. As consideration for the Services, Innocan will pay to AGORACOM an aggregate of $75,000 (plus applicable taxes) by way of the issuance of common shares of the Company (the “Shares“), subject to regulatory and Canadian Securities Exchange approval. The Shares are payable in five equal installments during the period from August 2020 to July 2021, as further provided for in the online marketing agreement between the Company and AGORACOM. The number of Shares to be issued under each installment will be determined by using the closing price of the common shares of Innocan on the last trading day following each period during which the Services were provided.

AGORACOM will initiate Innocan’s “HUB” which may be found at: https://agoracom.com/ir/InnocanPharma

George Tsiolis, AGORACOM’s Founder, stated, “With the cannabis markets having consolidated over the past year due to failed business plans, investors are now demanding better companies with real businesses, products, and revenues that are supported by real growth plans. Innocan checks all the boxes, with commercialization of their consumer products now commencing, as well as, a pharmaceutical division that is developing the pharmaceutical guided missile to defeat coronavirus-infected lungs. It won’t take long for the community to realize Innocan will form part of the new leadership group of cannabis driven pharmaceutical companies. We’re proud to take the Innocan story to the world.”

About Cloud 9 Switzerland LLC

The Cloud 9 Group of private companies comprises the founding company Cloud 9 Switzerland LLC, and its subsidiaries in Jamaica and France. All three are active in the health and wellness sectors, developing, producing and commercialising pharmaceuticals and nutraceuticals based on medicinal and aromatic plants – notably hemp/cannabis sativa L. Since its founding in July 2017, the group has focused on developing and commercialising premium hemp and cannabis products, building a unique portfolio of food, beverages and cosmetics; selective third party brands; and prescription and over-the-counter (OTC) medicines.

About AGORACOM

Agoracom provides online marketing, broadcasting, conferencing and investor relations services to North American small and mid-cap public companies, with more than 300 companies served. AGORACOM states that it is the home of more than 7.7 million users who have visited its site 55.2 million times and read over 600 million pages of information over the last 10 years. AGORACOM further states that the average user visit of 8min 43sec is more than double that of global financial sites, which can be attributed to the implementation and enforcement of the strongest moderation rules in the industry.

About Innocan

The Company, through its wholly owned subsidiary, Innocan Pharma Ltd., is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD“). Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

The Company signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. The Company plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Datametrex $DM.ca Announces Purchase Orders and Completion of Delivery

Posted by AGORACOM-JC at 8:08 AM on Thursday, August 20th, 2020
  • Announced that it has received a second Purchase Order from Canadian Royalties Inc., a private mining company operating a copper and nickel mine in Nunavik, Quebec
  • This P.O. is for 2,000 tests with 1copy test kits, approximately $200,000 in sales, making the total sales to date approximately $400,000
  • Datametrex has completed delivery to another Canadian mining company for their South America mining site and has completed shipping 30,000 1copy test kits, 30,000 UTMs, a PCR machine, 30,000 RNA extraction kits and an RNA extraction machine
  • Approximate sales from this transaction is $850,000.The Company received its payment in full

TORONTO, Aug. 20, 2020 — Datametrex AI Limited (the “Company” or “Datametrex“) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that it has received a second Purchase Order (“P.O.”) from Canadian Royalties Inc. (“CRI”), a private mining company operating a copper and nickel mine in Nunavik, Quebec. This P.O. is for 2,000 tests with 1copy test kits, approximately $200,000 in sales, making the total sales to date approximately $400,000.

Canadian Royalties is committed to occupational health and safety, and with the help of Datametrex, Canadian Royalties is endeavouring to allow its workforce to continue to operate with less risk. Canadian Royalties has over 1,000 employees at the Nunavik Nickel Project. On average, 400 people live and work on constant rotation at the Project, whether at the EXPO or Deception Bay camps, all on a fly-in / fly-out rotation.

Datametrex has completed delivery to another Canadian mining company for their South America mining site and has completed shipping 30,000 1copy test kits, 30,000 UTMs, a PCR machine, 30,000 RNA extraction kits and an RNA extraction machine. Approximate sales from this transaction is $850,000.The Company received its payment in full.

“We are thrilled to be able to support the operations of these mining companies as they endeavour to protect their employees and minimize the dangers, risks, and impacts that COVID-19 has brought,” stated Marshall Gunter, CEO of Datametrex.

About Canadian Royalties Inc.
Canadian Royalties Inc. (“CRI”) is a private mining company based in Montreal that operates a copper and nickel mine in Nunavik (province of Quebec), under the name Nunavik Nickel Project (“Project”). CRI is solely owned by their parent company in China, Jilin Jien Nickel Industry Co., Ltd. Canadian Royalties Inc. will engage the commitment and involvement of all of its employees and contractors to ensure that environmental, health and safety performance objectives are met. Additional information on Canadian Royalties is available at https://www.canadianroyalties.com/

About Datametrex
Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Esports Entertainment Group $GMBL Partners with Twin River Worldwide Holdings, Inc. to Launch Online Sports Betting in New Jersey $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca $TRWH

Posted by AGORACOM-JC at 8:01 AM on Thursday, August 20th, 2020
  • Entered into a multi-year partnership with Twin River Worldwide Holdings, Inc. (NYSE: TRWH)
  • Partnership will lead to the launch of Esports Entertainment Group’s proprietary mobile sports betting product in the state of New Jersey, pending Twin River obtaining the necessary regulatory approvals to complete its acquisition of Bally’s Atlantic City Hotel & Casino in Atlantic City, New Jersey
  • “We are excited to partner with Twin River as we bring mobile sports betting to the New Jersey market,” added Grant Johnson, CEO of Esports Entertainment Group

BIRKIRKARA, Malta, August 20, 2020 Esports Entertainment Group, Inc. (NasdaqCM: GMBL, GMBLW) ( the “Company”), a licensed online gambling company with a focus on esports wagering and 18+ gaming, entered into a multi-year partnership with Twin River Worldwide Holdings, Inc. (NYSE: TRWH).

The partnership will lead to the launch of Esports Entertainment Group’s proprietary mobile sports betting product in the state of New Jersey, pending Twin River obtaining the necessary regulatory approvals to complete its acquisition of Bally’s Atlantic City Hotel & Casino in Atlantic City, New Jersey. Upon the acquisition, Twin River acquires the right to three online sports betting skins in New Jersey, leading to the creation of this partnership.

“We are excited to partner with Twin River as we bring mobile sports betting to the New Jersey market,” added Grant Johnson, CEO of Esports Entertainment Group. “When we completed our IPO on Nasdaq earlier this year, it was with the intention of expanding our operations in the US. With this partnership, we’re delivering on that goal.”

“Esports Entertainment will be a great addition to our growing partnerships with Sportsbook leaders around the world, as we currently operate sportsbooks in Rhode Island, Colorado, Delaware and Mississippi,” says George Papanier, President and CEO of Twin River Worldwide Holdings. “Bringing this new, unique offering to the AC market with a prominent gaming partner is one of the many exciting changes we have in store for Atlantic City in the months to come.”

About Twin River Worldwide Holdings, Inc.
Twin River Worldwide Holdings, Inc. owns and manages nine casinos, two in Rhode Island, two in Mississippi, one in Delaware, one in Missouri and three casinos as well as a horse racetrack that has 13 authorized OTB licenses in Colorado. Properties include Twin River Casino Hotel (Lincoln, RI), Tiverton Casino Hotel (Tiverton, RI), Hard Rock Hotel & Casino (Biloxi, MS), Casino Vicksburg (formerly Lady Luck Casino Vicksburg in Vicksburg, MS), Dover Downs Hotel & Casino (Dover, DE), Casino KC (formerly Isle of Capri Casino in Kansas City, MO), Golden Gates Casino (Black Hawk, CO), Golden Gulch Casino (Black Hawk, CO), Mardi Gras Casino (Black Hawk, CO), and Arapahoe Park racetrack (Aurora, CO). Its casinos range in size from 603 slots and 8 electronic table games to properties with over 4,100 slots, approximately 125 table games, and 48 stadium gaming positions, along with hotel and resort amenities. Its shares are traded on the New York Stock Exchange under the ticker symbol “TRWH.” For more information, visit www.twinriverwwholdings.com.

About Esports Entertainment Group

Esports Entertainment Group, Inc. is a licensed online gambling company with a specific focus on esports wagering and 18+ gaming. Esports Entertainment offers fixed odds wagering, fantasy and pools on various esports events in a licensed, regulated and secure platform at vie.gg and owns and operates online sports book, SportNation.bet. In addition, Esports Entertainment intends to offer users from around the world the ability to participate in multiplayer mobile and PC video game tournaments for cash prizes. Esports Entertainment is led by a team of industry professionals and technical experts from the online gambling and the video game industries, and esports. The Company holds a license to conduct online gambling and 18+ gaming on a global basis in the UK, Ireland, Malta and Curacao. The Company maintains offices in New Jersey, the UK and Malta. For more information visit www.esportsentertainmentgroup.com.


FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact:

U.S. Investor Relations 
RedChip Companies, Inc.
Dave Gentry
407-491-4498
[email protected]

Media & Investor Relations Inquiries
AGORACOM
[email protected]
http://agoracom.com/ir/eSportsEntertainmentGroup